Callow Brennan, He Xiaobing, Juriga Nicholas, Mangum Kevin D, Joshi Amrita, Xing Xianying, Obi Andrea, Chattopadhyay Abhijnan, Milewicz Dianna M, O'Riordan Mary X, Gudjonsson Johann, Gallagher Katherine, Davis Frank M
Section of Vascular Surgery, Department of Surgery, and.
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
JCI Insight. 2025 Jan 23;10(2):e183959. doi: 10.1172/jci.insight.183959.
Abdominal aortic aneurysms (AAA) are a life-threatening cardiovascular disease for which there is a lack of effective therapy preventing aortic rupture. During AAA formation, pathological vascular remodeling is driven by vascular smooth muscle cell (VSMC) dysfunction and apoptosis, for which the mechanisms regulating loss of VSMCs within the aortic wall remain poorly defined. Using single-cell RNA-Seq of human AAA tissues, we identified increased activation of the endoplasmic reticulum stress response pathway, PERK/eIF2α/ATF4, in aortic VSMCs resulting in upregulation of an apoptotic cellular response. Mechanistically, we reported that aberrant TNF-α activity within the aortic wall induces VSMC ATF4 activation through the PERK endoplasmic reticulum stress response, resulting in progressive apoptosis. In vivo targeted inhibition of the PERK pathway, with VSMC-specific genetic depletion (Eif2ak3fl/fl Myh11-CreERT2) or pharmacological inhibition in the elastase and angiotensin II-induced AAA model preserved VSMC function, decreased elastin fragmentation, attenuated VSMC apoptosis, and markedly reduced AAA expansion. Together, our findings suggest that cell-specific pharmacologic therapy targeting the PERK/eIF2α/ATF4 pathway in VSMCs may be an effective intervention to prevent AAA expansion.
腹主动脉瘤(AAA)是一种危及生命的心血管疾病,目前缺乏预防主动脉破裂的有效治疗方法。在AAA形成过程中,病理性血管重塑由血管平滑肌细胞(VSMC)功能障碍和凋亡驱动,而主动脉壁内VSMC丢失的调节机制仍不清楚。通过对人类AAA组织进行单细胞RNA测序,我们发现主动脉VSMC中内质网应激反应途径PERK/eIF2α/ATF4的激活增加,导致凋亡细胞反应上调。从机制上讲,我们报道主动脉壁内异常的TNF-α活性通过PERK内质网应激反应诱导VSMC ATF4激活,导致进行性凋亡。在弹性蛋白酶和血管紧张素II诱导的AAA模型中,通过VSMC特异性基因缺失(Eif2ak3fl/fl Myh11-CreERT2)或药物抑制对PERK途径进行体内靶向抑制,可保留VSMC功能,减少弹性蛋白片段化,减轻VSMC凋亡,并显著减少AAA扩张。总之,我们的研究结果表明,针对VSMC中PERK/eIF2α/ATF4途径的细胞特异性药物治疗可能是预防AAA扩张的有效干预措施。